Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome.

[1]  J. Saul,et al.  The Pediatric Heart Network: A Primer for the Conduct of Multicenter Studies in Children with Congenital and Acquired Heart Disease , 2006, Pediatric Cardiology.

[2]  L. Bonewald.  Regulation and regulatory activities of transforming growth factor beta. , 1999, Critical reviews in eukaryotic gene expression.

[3]  D. Judge,et al.  TGF-β–dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome , 2004 .

[4]  Hanns-Georg Klein,et al.  Marfan Database (third edition): new mutations and new routines for the software , 1998, Nucleic Acids Res..

[5]  N. Kouchoukos,et al.  Life expectancy in the Marfan syndrome. , 1995, The American journal of cardiology.

[6]  Richard P Visconti,et al.  Codistribution analysis of elastin and related fibrillar proteins in early vertebrate development. , 2003, Matrix biology : journal of the International Society for Matrix Biology.

[7]  D. Rifkin,et al.  Latent Transforming Growth Factor β-binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein* , 2003, The Journal of Biological Chemistry.

[8]  J. Ware,et al.  Applied Longitudinal Analysis , 2004 .

[9]  L. Bonewald,et al.  Role of the Latent Transforming Growth Factor β–Binding Protein 1 in Fibrillin‐Containing Microfibrils in Bone Cells In Vitro and In Vivo , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  A. Amery,et al.  Relationship between blood level of atenolol and pharmacologic effect , 1977, Clinical pharmacology and therapeutics.

[11]  R. Pyeritz,et al.  Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome. , 1994, The American journal of cardiology.

[12]  J. Dean.  Management of Marfan syndrome , 2002, Heart.

[13]  Marc K. Halushka,et al.  Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.

[14]  Wolfram Kress,et al.  A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2 , 2005, Nature Genetics.

[15]  John A Elefteriades,et al.  Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. , 2002, The Annals of thoracic surgery.

[16]  John A Elefteriades,et al.  Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. , 2006, The Annals of thoracic surgery.

[17]  Jan G P Tijssen,et al.  Aortic stiffness and diameter predict progressive aortic dilatation in patients with Marfan syndrome. , 2004, European heart journal.

[18]  E. Murphy,et al.  Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. , 1994, The New England journal of medicine.

[19]  D. Rifkin,et al.  Latent transforming growth factor-beta: structural features and mechanisms of activation. , 1997, Kidney international.

[20]  R E Pyeritz,et al.  Revised diagnostic criteria for the Marfan syndrome. , 1996, American journal of medical genetics.

[21]  D. Arking,et al.  Dysregulation of TGF-β activation contributes to pathogenesis in Marfan syndrome , 2003, Nature Genetics.

[22]  J. Coselli,et al.  Replacement of the aortic root in patients with Marfan's syndrome. , 1999, The New England journal of medicine.

[23]  D. Judge,et al.  Marfan's syndrome , 2005, The Lancet.

[24]  H. Koyanagi,et al.  Angiotensin II Type 2 Receptor Mediates Vascular Smooth Muscle Cell Apoptosis in Cystic Medial Degeneration Associated With Marfan’s Syndrome , 2001, Circulation.

[25]  K. K. Lan,et al.  Discrete sequential boundaries for clinical trials , 1983 .

[26]  Kevin B. Jones,et al.  Growth and maturation in Marfan syndrome. , 2002, American journal of medical genetics.

[27]  A J Man in't Veld,et al.  Evaluation of importance of central effects of atenolol and metoprolol measured by heart rate variability during mental performance tasks, physical exercise, and daily life in stable postinfarct patients. , 1995, Circulation.

[28]  M. Roman,et al.  Phenotypic features and impact of beta blocker or calcium antagonist therapy on aortic lumen size in the Marfan syndrome. , 1999, The American journal of cardiology.

[29]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[30]  R. Pyeritz,et al.  Marfan syndrome: current and future clinical and genetic management of cardiovascular manifestations. , 1993, Seminars in thoracic and cardiovascular surgery.

[31]  Dionne A. Graham,et al.  Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome. , 2007, The Journal of pediatrics.

[32]  B. McCrindle,et al.  Usefulness of enalapril versus propranolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. , 2005, The American journal of cardiology.

[33]  Ada Hamosh,et al.  Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene , 1991, Nature.

[34]  R. Glanville,et al.  Purification and partial characterization of fibrillin, a cysteine-rich structural component of connective tissue microfibrils. , 1991, The Journal of biological chemistry.